Cardiac catheterisation: radiation doses and lifetime risk of malignancy

Kunadian Vijayalakshmi, Dee Kelly, Claire-Louise Chapple, et al.

*Heart* 2007 93: 370-371
doi: 10.1136/hrt.2006.098731

Updated information and services can be found at:
http://heart.bmj.com/content/93/3/370.full.html

These include:

**Supplemental Material**
http://heart.bmj.com/content/suppl/2007/02/19/93.3.370.DC1.html

**References**
This article cites 5 articles, 3 of which can be accessed free at:
http://heart.bmj.com/content/93/3/370.full.html#ref-list-1

Article cited in:
http://heart.bmj.com/content/93/3/370.full.html#related-urls

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic collections**
Articles on similar topics can be found in the following collections

- Clinical diagnostic tests (18878 articles)
- Epidemiology (4829 articles)

**Notes**

To order reprints of this article go to:
http://heart.bmj.com/cgi/reprintform

To subscribe to *Heart* go to:
http://heart.bmj.com/subscriptions
Cardiac catheterisation: radiation doses and lifetime risk of malignancy

Kunadian Vijayalakshmi, Dee Kelly, Claire-Louise Chapple, David Williams, Robert Wright, Michael J Stewart, James A Hall, Andrew Sutton, Adrian Davies, John Haywood, Mark A de Belder

RESULTS

The descriptions of the projections used, conversion factors and demographic details of the patients studied are available in the supplementary report. Table 1 summarises the screening time, DAP, effective dose and estimated risk of malignancy for the different diagnostic cardiac catheterisation procedures are incomplete, and there are no national diagnostic reference levels for individual procedures.

We undertook this study with the aim of establishing local patient doses for six different diagnostic cardiac catheterisation procedures by looking at screening times and DAP results, and then establishing the effective dose. From these values, we estimated the patient risk in each specific procedure group.

METHOD

We prospectively collected data on 4398 diagnostic cardiac examinations carried out in a regional cardiac catheter laboratory over a period of 3 years. We did not include patients who had coronary angiography and went on to have revascularisation. The patients’ demographic details and the examination details were recorded (including screening time, number of acquisitions and number of cine frames).

The x-ray equipment used was a digital Philips Polydagnost C2 single-plane image-intensifier system (installed in 1992), which has an automatic control of x-ray exposure parameters. The average tube potential was 80 kVp (kilovoltage peak) and the total filtration was 4 mm aluminium (equivalent thickness of aluminium). The tube potential and the filtration were kept constant throughout all procedures. A diamentor (PTW-Physikalische Technische Werkstaetten, Freiberg) was used to measure the DAP. The recorded DAP values were corrected to a standard patient size. Effective dose measured in milliSieverts was calculated from the DAP reading using conversion factors for the various projections corresponding to a filtration of 4 mm aluminium and a mean tube kilovoltage of 80 kV as described previously. The proportion of total DAP assigned to each projection was estimated for each of the six diagnostic groups in the study, to derive a conversion factor for each examination group (0.23 mSv/Gy cm² for right anterior oblique views and 0.205 mSv/Gy cm² for left anterior oblique views).

We estimated the risk of malignancy for each specific examination from the effective dose values. Published reports indicate an estimate of 2.5% per Sievert (2.5 × 10−2/Sv or 1 in 40 000/mSv) additional lifetime risk of fatal cancer for a population between the ages of 40 and 60 years, and this figure has been used for comparative purposes here. Additional details and the methods of statistical analysis are available in a supplementary report at http://heart.bmj.com-supplemental.

DISCUSSION

The potential harmful effects of radiation are documented along with permitted recommended safe dose limits to staff (International Commission on Radiological Protection). Two types of radiation effects may occur: deterministic (skin erythema and ulceration) and stochastic effects. The risk of long-term stochastic effects (eg, cancer, leukaemia) is usually assessed by effective dose, which makes some allowance for the properties of the radiation concerned and for non-uniform distribution of radiation over the body. We did not observe any deterministic effect in the current patient population. We did not perform long-term follow-up of these patients to evaluate the appearance of stochastic effects; the estimated frequency of malignancy would require a long-term follow-up of a cohort rather than ours to prospectively validate our estimates.

The DAP measurements have been widely used in previous studies either as a means of comparison of radiation dose or as a step for estimation of risk. Our results on the DAP measurements and effective dose are comparable to previous studies. However, this is the first study to describe in detail the hypothetical additional LROM in patients undergoing different radiological cardiac diagnostic procedures. This study also provides diagnostic reference levels as recommended by the...
International Commission on Radiation Protection (ICRP 60), as directed in Europe by Council Directive 97/43/Euratom and as implemented in the UK by the Ionising Radiation (Medical Exposure) Regulations 2000.

In a previous report, the mortality associated with cardiac catheterisation and coronary angiography was 0.11%. The incidence of total major complications was 1.7%. Living in Cornwall (UK) has an additional radiation of 7 mSv/year and a flight to the US has an additional radiation dose of 40–50 mSv.

The typical effective dose for a chest x-ray (PA) is 0.02 mSv and for angiography is 10 mSv. Magnetic resonance coronary angiography does not involve radiation, and nuclear medicine involves 8–20 mSv of radiation.

The risks associated with coronary heart disease itself and the procedure of coronary angiography are relatively high compared with the hypothetical additional lifetime risk of malignancy in patients undergoing different radiological cardiac diagnostic procedures. Nevertheless, the additional LROM should not be ignored, particularly for younger patients, especially given the high numbers of cardiac procedures performed worldwide. In addition, the information provided allows informed consent for asymptomatic patients undergoing repeat coronary catheterisation as part of a clinical trial rather than for a specific clinical indication.

The radiation dose to the patient can be minimised by opening the iris on the television camera, allowing a lower increase in beam intensity and also by using flat panel detectors which have more sophisticated controls. To minimise scatter, an air gap between the patient and the detector can be used. In addition, the need for left ventriculography can be questioned if the relevant information can be acquired by non-invasive means.

More complex cardiac radiological procedures are associated with higher radiation doses, thereby greatly increasing the lifetime risk of malignancy. Every additional procedure must always be justified by a positive balance of benefit over risk for each patient. Stochastic risks of radiation by and large should not greatly affect this judgement, given that non-radiation risks are an order of magnitude higher.

Additional details and statistical analysis methods are available at http://heart.bmj.com/supplemental

### Authors’ affiliations
Kunadian Vijayalakshmi, Dee Kelly, David Williams, Robert Wright, Michael J Stewart, James A Hall, Andrew Sutton, Adrian Davies, John Haywood, Mark A de Belder, Departments of Cardiology and Medical Physics, The James Cook University Hospital, Middlesbrough, UK
Claire-Louise Chapple, Regional Medical Physics Department, Newcastle General Hospital, Newcastle upon Tyne, UK

Competing interests: None declared.

Correspondence to: Dr M A de Belder, Department of Cardiology, The James Cook University Hospital, Marton Road, Middlesbrough TS4 3BW, UK; mark.debelder@stees.nhs.uk

Accepted 7 August 2006

### REFERENCES

---

**Table 1** Screening time (s), dose–area product (Gy cm²), effective dose (mSv) and estimated risk (%) of malignancy for diagnostic cardiac imaging

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number</th>
<th>Screening time</th>
<th>DAP (Gy cm²)</th>
<th>ED (mSv)</th>
<th>Risk (%)</th>
<th>Additional risk of cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.COR</td>
<td>464</td>
<td>240.7 (333.9, 114)</td>
<td>20.1 (17.7, 15.6)</td>
<td>4.4</td>
<td>0.011</td>
<td>1 in 9000</td>
</tr>
<tr>
<td>A.LVC</td>
<td>3288</td>
<td>199 (242, 120)</td>
<td>21.7 (11.9, 19.1)</td>
<td>4.8</td>
<td>0.012</td>
<td>1 in 8000</td>
</tr>
<tr>
<td>RLVC</td>
<td>207</td>
<td>529.9 (398, 420)</td>
<td>32.1 (20.3, 27.4)</td>
<td>7.0</td>
<td>0.018</td>
<td>1 in 6000</td>
</tr>
<tr>
<td>A.LAC</td>
<td>194</td>
<td>414.6 (412, 279)</td>
<td>33 (18, 29.4)</td>
<td>7.4</td>
<td>0.018</td>
<td>1 in 6000</td>
</tr>
<tr>
<td>A.CAB</td>
<td>175</td>
<td>697 (486, 558)</td>
<td>40.3 (18, 37.7)</td>
<td>8.9</td>
<td>0.022</td>
<td>1 in 5000</td>
</tr>
<tr>
<td>A.CAC</td>
<td>70</td>
<td>815.3 (487.5, 732)</td>
<td>51.4 (22.6, 46.8)</td>
<td>11.5</td>
<td>0.029</td>
<td>1 in 3000</td>
</tr>
</tbody>
</table>

A.CAB, ventriculography, coronaries and graft studies; A.CAC, aortogram, coronaries and graft study; A.COR, coronaries only; A.LAC, aortogram and coronaries; A.LVC, left ventriculography (LV) and coronaries; DAP, dose–area product; ED, effective dose; RLVC, right heart catheterisation with A.LVC.

Values are expressed as mean (SD, median).